The Impact of Hyperosmolarity on Long-Term Outcome in Patients Presenting with Severe Hyperglycemic Crisis: A Population Based Study

Abstract

Aims We compared characteristics of patients with hyperglycemic hyperosmolar state (HHS) and patients with severe hyperglycemia without the signs of hyperosmolarity and ketoacidosis; analyzed long-term all-cause mortality and potential prognostic factors.

Methods The studied population included 261 749 adults. HHS was diagnosed in patients with plasma glucose >33.0 mmol/L, ketonuria <1+, and serum osmolarity >320 mmol/L. Patients with plasma glucose >33.0 mmol/L, ketonuria <1+ and serum osmolarity <320 mmol/L were considered as controls (nHHS).

Results During the 5-year period, we observed 68 episodes of HHS in 66 patients and 51 patients with nHHS. Patients with HHS were significantly older, had lower BMI, higher serum C-reactive protein and used diuretics and benzodiazepines more frequently. Mortality rates one, three and 12 months after admission were 19.0, 32.1 and 35.7% in the HHS group, and 4.8, 6.3 and 9.4% in the nHHS group (P<0.001). However, after adjustment for patient age, these differences were not statistically significant. In multivariate Cox regression in HHS group, mortality was positively associated with age, male gender, leukocyte count, amylase, presence of dyspnea and altered mental status, and the use of benzodiazepines, ACE inhibitors and sulphonylureas, while it was inversely associated with plasma glucose, bicarbonate, and the use of thiazides and statins. A nomogram derived from these variables had an accuracy of 89% in predicting lethal outcome.

Conclusions Infection, use of furosemide and benzodiazepines may be important precipitating factors of HHS. Prospective clinical trials are mandatory to analyze the safety of ACE-inhibitors and benzodiazepines in elderly patients with diabetes.

Key words

diabetes mellitus type 2 - hyperglycemic hyperosmolar state - mortality - angiotensin-converting enzyme inhibitors - benzodiazepines - precipitating factors

• References

• 1 Piniés JA, Cairo G, Gaztambide S. et al. Course and prognosis of 132 patients with diabetic non ketotic hyperosmolar state. Diabetes Metab 1994; 20: 43-48
• 2 Wachtel TJ, Tetu-Mouradjian LM, Goldman DL. et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991; 6: 495-502
• 3 Bagdure D, Rewers A, Campagna E. et al. Epidemiology of hyperglycemic hyperosmolar syndrome in children hospitalized in USA. Pediatr Diabetes 2013; 14: 18-24
• 4 Rosenthal NR, Barrett EJ. An assessment of insulin action in hyperosmolar hyperglycemic nonketotic diabetic patients. J Clin Endocrinol Metab 1985; 60: 607-610
• 5 Trence DL, Hirsch IB. Hyperglycemic crises in diabetes mellitus type 2. Endocrinol Metab Clin North Am 2001; 30: 817-831
• 6 Chung ST, Perue GG, Johnson A. et al. Predictors of hyperglycaemic crises and their associated mortality in Jamaica. Diabetes Res Clin Pract 2006; 73: 184-190
• 7 Chu CH, Lee JK, Lam HC. et al. Prognostic factors of hyperglycemic hyperosmolar nonketotic state. Chang Gung Med J 2001; 24: 345-351
• 8 Keller U, Berger W, Ritz R. et al. Course and prognosis of 86 episodes of diabetic coma. A five year experience with a uniform schedule of treatment. Diabetologia 1975; 11: 93-100
• 9 Rimailho A, Riou B, Dadez E. et al. Prognostic factors in hyperglycemic hyperosmolar nonketotic syndrome. Crit Care Med 1986; 14: 552-554
• 10 Fadini GP, de Kreutzenberg SV, Rigato M. et al. Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. Diabetes Res Clin Pract. 2011; 94: 172-179
• 11 Wachtel TJ, Silliman RA, Lamberton P. Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med 1987; 147: 499-501
• 12 Chuengsamarn S, Rattanamongkolgul S, Sittithumcharee G. et al. Association of serum high-sensitivity C-reactive protein with metabolic control and diabetic chronic vascular complications in patients with type 2 diabetes. Diabetes Metab Syndr Clin Res Rev. 2016;
• 13 Fonseca V, Phear DN. Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diuretics. Br Med J (Clin Res Ed) 1982; 284: 36-37
• 14 Ahuja N, Palanichamy N, Mackin P. et al. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. J Psychopharmacol 2010; 24: 125-130
• 15 Greenblatt DJ, Harmatz JS, Shapiro L. et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-1698
• 16 Yadav D, Nair S, Norkus EP. et al. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: Incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000; 95: 3123-3128
• 17 Zillich AJ, Garg J, Basu S. et al. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006; 48: 219-224
• 18 Sica DA, Carter B, Cushman W. et al. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011; 13: 639-643
• 19 Morgan CL, Mukherjee J, Jenkins-Jones S. et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; 16: 977-983
• 20 Eurich DT, Majumdar SR, Tsuyuki RT. et al. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004; 27: 1330-1334
• 21 Schoolwerth AC, Sica DA, Ballermann BJ. et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-1991
• 22 Shin SJ, Lee YJ, Hsiao PJ. et al. Increased urinary atrial natriuretic peptide-like immunoreactivity excretion but decreased plasma atrial natriuretic peptide concentration in patients with hyperosmolar-hyperglycemic nonketotic syndrome. Diabetes Care 1999; 22: 1181-1185